NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits can be filed on behalf of shareholders of Fate Therapeutics, Inc. FATESotera Health Co. SHCArgo Blockchain Plc, Inc. ARBKand National Vision Holdings, Inc. EYE. Shareholders have until the deadlines below to petition the court to be lead plaintiff. For more information on each case, see the link provided.

Fate Therapeutics, Inc. FATE

Class period: April 2, 2020 – January 5, 2023

Lead Plaintiff Deadline: March 22, 2023

Fate is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies for the treatment of cancer and immune disorders.

On April 2, 2020, after the market close, Fate announced it had entered into a global collaboration and option agreement with Janssen Biotech, Inc. (“Janssen”), one of Johnson & Johnson’s Janssen Pharmaceutical Companies, for cell-based cancer immunotherapies in which Fate received an upfront payment of US$50 million (the “Janssen Collaboration Agreement”). In addition, Fate was eligible for up to $3 billion in various milestone payments and double-digit royalties on all net sales from the collaboration. In the news on April 3, 2020, Fate’s share price is up 8.8%.

Throughout the Class Period, the defendants made materially false and misleading statements regarding the Company’s business, operations and compliance policies. In particular, the Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Janssen Cooperation Agreement was less sustainable than Fate had represented to the investors; (ii) accordingly, certain clinical programs, milestone payments and royalties payments related to the Janssen Collaboration Agreement may not qualify as future revenue streams; (iii) as a result, Fate had the effects of the Janssen Collaboration Agreement on Fates…